Once it takes effect, the bipartisan deal will make 600,000+ North Carolinians newly eligible for lifesaving care, including cancer screenings and treatment.  ..read more

This February, Walgreens continues their annual spring fundraiser with The Leukemia & Lymphoma Society and Susan G. Komen. During this multi-year partnership, Walgreens pledges to donate more than $25 million by 2024 to advance research for tough-to-treat cancers and increase equitable access to care ..read more

LLS Chief Medical Officer, Dr. Gwen Nichols, had the privilege of moderating an Researcher Panel attended by LLS college club members from nearly 30 universities across the country. These clubs bring together students interested in pursuing health-related careers and provide opportunities to hear from scientists working to better understand and treat blood cancers ..read more

We’ve come a long way and we continue to make substantial progress. The outlook for blood cancer patients is better than ever, but it’s still nowhere near good enough. With more than $233 million dollars currently committed to research into every type of blood cancer, you can be sure LLS ..read more

LLS and blood cancer advocates are celebrating after our efforts helped make two bills become law in California, advancing health equity and improving cancer care for thousands ..read more

The Food and Drug Administration (FDA) approved azacitidine (Vidaza®) for pediatric patients 1 month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML). JMML is an aggressive and difficult to treat disease ..read more

..read more

The American Society of Hematology (ASH) annual meeting is the premier scientific forum on blood cancers. More than 5,000 potentially game-changing research abstracts were presented at this year’s meeting. Every year, I come away with a strengthened sense of hope about new treatments on the horizon and renewed pride in The Leukemia & Lymphoma Society’s (LLS) role in supporting so many of them ..read more